Benque A, Bommelaer G, Rosental G
Food and Drug Administration (FDA) has yet to approve an oral GLP-1 therapy for chronic weight management
Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa Central Africa Key Players Insights (Revenue, USD Bn, 2021 - 2033) Eli Lilly and Company Sources Primary Research Interviews Interviews with healthcare providers (e.g., Diabetologist, immunologists) Interviews with key opinion leaders (KOLs) Interviews with pharmacists and medical professionals Interviews with patients using Mounjaro Databases National Health Service (NHS) U.K
This approach not only supports muscle health but also promotes satiety, which can be particularly beneficial for managing hunger on semaglutide
This early detection can be key to successful treatment.
Whilst these medications offer significant metabolic benefits, gastrointestinal side effectsparticularly constipationare commonly reported by patients
